v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash $ 7,739,323 $ 5,069,266
Advances on research and development contract services 12,993 76,898
Prepaid insurance 75,284 67,311
Other prepaid expenses and current assets 62,500 15,000
Total current assets 7,890,100 5,228,475
Total assets 7,890,100 5,228,475
Current liabilities:    
Accounts payable and accrued expenses 148,871 190,292
Accrued offering costs 10,467
Research and development contract liabilities 93,529 15,765
Total current liabilities 242,400 216,524
Commitments and contingencies
Stockholders' equity:    
Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares - 729,167 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 13,538,259 shares and 12,402,157 shares at March 31, 2021 and December 31, 2020, respectively 1,354 1,240
Additional paid-in capital 36,227,258 31,864,479
Accumulated deficit (32,080,912) (30,353,768)
Total stockholders' equity 7,647,700 5,011,951
Total liabilities and stockholders' equity $ 7,890,100 $ 5,228,475

Source